Vita Life Sciences (ASX:VLS) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

VLS Overzicht aandelen

Vita Life Sciences Limited, een onderneming actief in de gezondheidszorg, houdt zich bezig met de formulering, verpakking, distributie en verkoop van vitaminen en supplementen in Australië, Singapore, Maleisië, Thailand, Vietnam, Indonesië en China.

Over het bedrijf

VLS fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	0/6
Prestaties in het verleden	4/6
Financiële gezondheid	6/6
Dividenden	4/6

Beloningen

Verhandeld tegen 81.1% onder onze schatting van de reële waarde

De winst is de afgelopen 5 jaar met 19.8% per jaar gegroeid

Risicoanalyse

Onstabiel dividend track record

Heeft geen betekenisvolle marktkapitalisatie ( A$126M )

Vita Life Sciences Limited Concurrenten

Vitura Health

ASX:VIT

AU$42.0m

ECS Botanics Holdings

ASX:ECS

AU$23.8m

Neuren Pharmaceuticals

ASX:NEU

AU$1.9b

EZZ Life Science Holdings

ASX:EZZ

AU$200.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Vita Life Sciences
Historische aandelenkoersen
Huidige aandelenkoers	AU$2.22
52 Week Hoogtepunt	AU$2.50
52 Week Laag	AU$1.60
Bèta	0.46
11 maand verandering	-2.20%
3 maanden verandering	0.91%
1 Jaar Verandering	30.59%
33 jaar verandering	43.23%
5 jaar verandering	263.93%
Verandering sinds IPO	1,205.88%

Recent nieuws en updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Rendement voor aandeelhouders

	VLS	AU Pharmaceuticals	AU Markt
7D	2.8%	3.8%	1.1%
1Y	30.6%	98.5%	17.9%

Rendement versus industrie: VLS presteerde slechter dan de Australian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 98.5 % opleverde.

Rendement versus markt: VLS overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 17.9 %.

Prijsvolatiliteit

Is VLS's price volatile compared to industry and market?
VLS volatility
VLS Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: VLS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van VLS is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1947	n/a	Andrew O'Keefe	vitalifesciences.com

Vita Life Sciences Limited, een bedrijf in de gezondheidszorg, houdt zich bezig met het formuleren, verpakken, distribueren en verkopen van vitaminen en supplementen in Australië, Singapore, Maleisië, Thailand, Vietnam, Indonesië en China. Het bedrijf biedt ook verschillende mineralen, kruiden en superfoods. Daarnaast levert het producten voor therapeutische gebieden, zoals het zenuwstelsel; voedingsstoffen; urinegezondheid; gewichtsbeheersing; immuniteit; huid, haar en nagels; lever en spijsvertering; vruchtbaarheid, zwangerschap en postpartum; bloedsuikerbeheer; cardiovasculaire gezondheid; pijn en ontstekingen; gezondheid van mannen, vrouwen en kinderen; antioxidanten; botten, gewrichten en spieren; en ooggezondheid.

Vita Life Sciences Limited Samenvatting

Hoe verhouden de winst en inkomsten van Vita Life Sciences zich tot de beurswaarde?
VLS fundamentele statistieken
Marktkapitalisatie	AU$126.05m
Inkomsten(TTM)	AU$9.39m
Inkomsten(TTM)	AU$79.17m

13.4x

Koers/Winstverhouding

1.6x

P/S-verhouding

Is VLS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VLS resultatenrekening (TTM)
Inkomsten	AU$79.17m
Kosten van inkomsten	AU$32.77m
Brutowinst	AU$46.41m
Overige uitgaven	AU$37.01m
Inkomsten	AU$9.39m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.17
Brutomarge	58.61%
Nettowinstmarge	11.86%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde VLS op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.1%

Huidig dividendrendement

55%

Uitbetalingsratio

VLS Overzicht aandelen

Beloningen

Risicoanalyse

Vita Life Sciences Limited Concurrenten

ASX:VIT

AU$42.0m

ASX:ECS

AU$23.8m

ASX:NEU

AU$1.9b

ASX:EZZ

AU$200.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Now 22% undervalued

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Now 22% undervalued

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?